MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/643539
78 MARCH 2016 | Med Esthetics NEWS & EVENTS GALDERMA AND ZELTIQ ANNOUNCE COLLABORATION Galderma and ZELTIQ Aesthetics are teaming up to provide healthcare professionals and patients with better access to a range of technologies and procedures for facial rejuvenation and noninvasive fat reduction. The companies will create connections between the Galderma portfolio of aesthetic brands (such as Dysport, Restylane and Sculptra) and ZELTIQ's CoolSculpting procedure through their respective loyalty programs: ASPIRE Galderma Rewards (aspirerewards.com) and Crystal Rewards (coolsculpting.com). "At Galderma, we are focused on advancing skin health and driving category innovation for natural-looking results. Through this uniquely designed collaboration with ZELTIQ, we are bringing together leading facial aesthetic technology and noninvasive fat reduction to better serve and provide long-term value to our healthcare specialists, as well as increase awareness among consumers," said Kelly Huang, PhD, VP, Aesthetic and Corrective Business Unit, Galderma. THERMI250 CLEARED FOR CELLULITE REDUCTION The U.S. Food and Drug Administration (FDA) has cleared the Thermi250 (Thermi) temperature-controlled radiofrequency (RF) device for the temporary reduction of cellulite (treatments will be named ThermiSmooth). The high-powered, thermistor-regulated system features an array of electrodes and user-friendly graphic interface, and is indicated for both skin laxity and cellulite. The company has released preliminary results of a multicenter IRB-approved clinical study conducted in more than 90 sites across the U.S. to determine the device's effi cacy and safety for conditions such as wrinkles, skin laxity, body slimming and cellulite. The fi rst data documented the positive results of 14 patients presenting with abdominal laxity who received four treatments at two-week intervals; the study concluded that the device "is a safe and effective modality for noninvasive body slimming." BRANDT RESEARCH GRANT WINNER ANNOUNCED Abigail Waldman, MD, of Chicago is the fi rst research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. The fund—supported by The Allergan Foundation—promotes and supports the career development of cosmetic dermatologic surgeon-scientists focused on cosmetic treatments and patient care. It was established earlier this year to advance the legacy of Dr. Brandt, a longtime ASDS member who passed away in April. Dr. Waldman is currently enrolled in a cosmetic dermatologic surgery fellow- ship training program through the Mc- Gaw Medical Center of Northwestern University. She was awarded $41,500 for her research project, "Patient Motiva- tions and Preferences Regarding the Decision to Seek Cosmetic Dermato- logic Surgical Procedures: A Prospective Multicenter Study," in which she plans to interview current and prospective cosmetic patients to gather insights that can be used to ensure patients choose treatments that best match their desired outcomes. ALLERGAN ACQUIRES ANTERIOS, EXPANDS NEUROTOXIN PIPELINE Allergan has announced its acquisition of Anterios, a clinical-stage bio- pharmaceutical company developing a next-generation topical delivery system for botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an up-front payment of $90 million with potential development and commer- cialization milestone payments related to NDS, Anterios' proprietary delivery technology that enables local, targeted delivery of neurotoxins through the skin without injection. NATIONAL ROSACEA SOCIETY AWARDS RESEARCH GRANTS The National Rosacea Society (NRS) awarded funding for three new studies as part of its research grants program created to increase knowledge and understanding of rosacea. Gideon Smith, MD, assistant physician in the department of der- matology at Massachusetts General Hospital and instructor at Harvard University, and colleagues were awarded $25,000 to investigate whether individuals with rosacea may be at higher risk for other disorders involving the vascular system such as heart disease and high cholesterol. Lori Lee Stohl, MD, research associate in the department of dermatology at Weill Cornell Medical School, was awarded $25,000 to examine how norepinephrine and adenosine triphosphate (ATP), released during stress, may increase the number of mast cells, which have been linked to dysfunction of the innate immune system and the appearance of the signs and symptoms of rosacea. She will also study whether these chemicals induce cathelicidins, a peptide involved in the immune system that is also linked to rosacea. Daniel Popkin, MD, assistant professor of dermatology at Case Western Reserve University, and colleagues were awarded $25,000 earlier in 2015 to study the facial microbiomes of identical twins in whom only one has rosacea. Researchers interested in applying for grants may visit the research grants section of rosacea.org or contact: 888.662.5874, rosaceas@aol.com. High priority is given to studies relating to the pathogenesis, progression, mechanism of action, cell biology and potential genetic factors related to rosacea. Proposals relating to epidemiology, predisposition, quality of life and relationships with environmental and lifestyle factors may also be considered. The deadline for submitting proposals to receive a research grant in 2016 is June 17, 2016. TRIAL INITIATED FOR TOPICAL UNDEREYE BAGS SOLUTION Biotechnology company Topokine Therapeutics has initiated a Phase 2b/3 study of its lead product, XAF5 Ointment, for the reduction of steato- blepharon (undereye bags). Applied to the lower eyelids once nightly, the topical treatment penetrates the skin and acts pharmacologically on fat cells to shrink eye bags as an alternative to blepharoplasty surgery. Abigail Waldman, MD